ECSP024374A - Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa - Google Patents

Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa

Info

Publication number
ECSP024374A
ECSP024374A EC2002004374A ECSP024374A ECSP024374A EC SP024374 A ECSP024374 A EC SP024374A EC 2002004374 A EC2002004374 A EC 2002004374A EC SP024374 A ECSP024374 A EC SP024374A EC SP024374 A ECSP024374 A EC SP024374A
Authority
EC
Ecuador
Prior art keywords
derivatives
ylamina
synthease
tiazol
dihidro
Prior art date
Application number
EC2002004374A
Other languages
English (en)
Inventor
Dominique Damour
Jean-Christophe Carry
Erick Bacque
Antony Bigot
Serge Mignani
Claude Guyon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ECSP024374A publication Critical patent/ECSP024374A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)

Abstract

El presente invento concierne las composiciones farmacéuticas que contienen como principio activo un derivado del 4,5-dihidro- 1,3-tiazol-2-y lamina de fórmula (1), en donde R representa un radical -alq-S-alq-Ar, fenilo o fenil I sustituido por alcoxi o halógeno o una de sus sales farmacéuticamente aceptadas, los nuevos derivados de fórmula (1) y su preparación. Estos compuestos son útiles para prevenir y tratar enfermedades en las que una producción anormal de monóxido de nitrógeno (NO) por efecto de NO-sintetasa inducible (NOS-2) está implicada.
EC2002004374A 2000-06-09 2002-12-09 Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa ECSP024374A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0007396A FR2810036B1 (fr) 2000-06-09 2000-06-09 Derives de 4,5-dihydro-1,3-thiazol-2-ylamine, leur preparation et les compositions phamarceutiques les contenant

Publications (1)

Publication Number Publication Date
ECSP024374A true ECSP024374A (es) 2003-02-06

Family

ID=8851133

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004374A ECSP024374A (es) 2000-06-09 2002-12-09 Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa

Country Status (27)

Country Link
EP (1) EP1299103B1 (es)
JP (1) JP4171297B2 (es)
KR (1) KR20030017990A (es)
CN (1) CN1441673A (es)
AP (1) AP2002002707A0 (es)
AT (1) ATE305298T1 (es)
AU (2) AU6612301A (es)
BR (1) BR0111543A (es)
CA (1) CA2411572C (es)
DE (1) DE60113686T2 (es)
DK (1) DK1299103T3 (es)
DZ (1) DZ3366A1 (es)
EA (1) EA200300009A1 (es)
EC (1) ECSP024374A (es)
ES (1) ES2246327T3 (es)
FR (1) FR2810036B1 (es)
HR (1) HRP20020971A2 (es)
HU (1) HUP0300996A3 (es)
IL (1) IL153327A0 (es)
MA (1) MA25815A1 (es)
MX (1) MXPA02012072A (es)
NO (1) NO20025885L (es)
NZ (1) NZ522967A (es)
OA (1) OA12285A (es)
PL (1) PL360282A1 (es)
WO (1) WO2001093867A1 (es)
ZA (1) ZA200209770B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670720A1 (en) * 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzyme inhibitors
DE69416848T2 (de) * 1993-10-21 1999-07-08 Searle & Co Amidino-derivate als no-synthetase inhibitoren
AU4149696A (en) * 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
DE60113686T2 (de) 2006-07-13
CA2411572C (fr) 2009-11-10
BR0111543A (pt) 2003-07-01
DZ3366A1 (fr) 2001-12-13
AP2002002707A0 (en) 2002-12-31
HUP0300996A2 (hu) 2003-08-28
WO2001093867A1 (fr) 2001-12-13
OA12285A (en) 2006-05-12
NO20025885L (no) 2003-01-29
AU6612301A (en) 2001-12-17
JP4171297B2 (ja) 2008-10-22
ATE305298T1 (de) 2005-10-15
NZ522967A (en) 2005-07-29
DK1299103T3 (da) 2006-01-23
JP2003535135A (ja) 2003-11-25
ZA200209770B (en) 2004-03-02
EP1299103A1 (fr) 2003-04-09
CA2411572A1 (fr) 2001-12-13
IL153327A0 (en) 2003-07-06
HUP0300996A3 (en) 2006-02-28
PL360282A1 (en) 2004-09-06
MXPA02012072A (es) 2004-08-19
AU2001266123B2 (en) 2007-01-25
FR2810036A1 (fr) 2001-12-14
CN1441673A (zh) 2003-09-10
NO20025885D0 (no) 2002-12-06
EP1299103B1 (fr) 2005-09-28
HRP20020971A2 (en) 2005-02-28
EA200300009A1 (ru) 2003-04-24
ES2246327T3 (es) 2006-02-16
MA25815A1 (fr) 2003-07-01
KR20030017990A (ko) 2003-03-04
FR2810036B1 (fr) 2004-04-23
DE60113686D1 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
UY26872A1 (es) Derivados de la 4- fenil piridina
UY26968A1 (es) Agentes terapéuticos
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
DOP2010000148A (es) Derivados bis-(sulfonilzmino) en terapia 066
CR6643A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8520301A1 (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal
ES2213732T3 (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PA8591701A1 (es) Derivados de pirrolopirimidina
AR029766A1 (es) Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica
DOP2006000243A (es) Derivados de pirazina
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
ES2632798T3 (es) Uso de derivados de cumarina para la preparación de fármacos de tratamiento de enfermedades de la piel
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos